Breaking News Instant updates and real-time market news.

PODD

Insulet

$57.74

1.14 (2.01%)

06:07
09/28/17
09/28
06:07
09/28/17
06:07

Insulet opening manufacturing facility in Massachusetts

Insulet will host a groundbreaking celebration at its new manufacturing facility on a 26-acre site in Acton, Massachusetts. The new $100M facility is expected to create hundreds of local jobs. The company plans to begin production at this location in 2019.

PODD Insulet
$57.74

1.14 (2.01%)

07/13/17
BTIG
07/13/17
NO CHANGE
BTIG
Buy
Abbott, Bigfoot deal a 'major validation' for both, says BTIG
BTIG analyst Sean Lavin sees Abbott's (ABT) deal to collaborate with Bigfoot Biomedical as a major validation of both Abbott's Libre technology and the platform of Bigfoot, which he views as a leader in the development of automated pancreases. For Dexcom (DXCM), this is a missed opportunity that could also be a sign that its grip on the CGM market may fade over time, but the company still has multiple shots with other pump systems and remains the market leader of standalone CGM, said Lavin. Insulet (PODD) is well underway in developing its Horizon AP platform and is unlikely to switch from Dexcom for its CGM, added Lavin, who keeps a Buy rating on Abbott and a Neutral rating on Dexcom.
07/17/17
BTIG
07/17/17
DOWNGRADE
BTIG
Neutral
Insulet downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded Insulet to Neutral saying shares are fairly valued following recent share strength.
08/04/17
COWN
08/04/17
NO CHANGE
Target $63
COWN
Outperform
Insulet price target raised to $63 from $52 at Cowen
Cowen analyst Doug Schenkel raised his price target on Insulet to $63 from $52 following solid Q2 results. The analyst raised his estimates to account for the company going direct in Europe while also raising his long-term gross margin target. Schenkel, who also continues to see upside to 2019 estimates, reiterated his Outperform rating on Insulet shares.
09/15/17
LEHM
09/15/17
INITIATION
Target $65
LEHM
Overweight
Insulet initiated with an Overweight at Barclays
Barclays analyst Matthew Taylor started Insulet with an Overweight rating and $65 price target. The analyst sees upside to consensus estimates and notes his survey work and physician checks have been positive for the company.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.